If you've taken Reglan for weeks or longer, you may wonder about your risk for tardive dyskinesia, a condition involving involuntary movements. Research has established that prolonged use of metoclopramide is associated with this movement disorder, though individual risk varies. This page summarizes the evidence on who is most at risk and what factors may influence your chances.
Reglan (metoclopramide) is a medication approved for short-term treatment of symptomatic gastroesophageal reflux in adults and for relief of symptoms in adults with acute and recurrent diabetic gastroparesis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). However, its use carries a significant risk of tardive dyskinesia (TD), a potentially irreversible movement disorder. The FDA-approved prescribing information includes a boxed warning stating that metoclopramide, including Reglan, can cause TD, and that the risk increases with duration of treatment and total cumulative dosage (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). This warning also notes that Reglan is contraindicated in patients with a history of TD, and that the drug should be used for the shortest duration necessary, with periodic reassessment of the need for continued treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Tardive dyskinesia is characterized by involuntary, repetitive movements of the face, tongue, trunk, or extremities. The prescribing information describes TD as a syndrome of potentially irreversible and disfiguring movements, and notes that metoclopramide may suppress or partially suppress the signs of TD, potentially delaying diagnosis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The clinical presentation can vary, but typical features include grimacing, lip smacking, tongue protrusion, and rapid jerking movements of the limbs. The condition can be socially stigmatizing and functionally disabling.
The mechanistic pathway linking Reglan to TD involves the drug's action as a dopamine receptor antagonist in the central nervous system. Chronic blockade of dopamine D2 receptors in the striatum is thought to lead to upregulation of these receptors and supersensitivity to dopamine, which may contribute to the development of abnormal involuntary movements. The risk is dose-dependent and cumulative, with longer exposure increasing the likelihood of developing TD. The boxed warning emphasizes that in patients with diabetic gastroparesis, total treatment duration with metoclopramide products should not exceed 12 weeks, and if longer-term use is unavoidable, routine monitoring for signs and symptoms of TD is recommended (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). For gastroesophageal reflux, the maximum approved treatment duration is 12 weeks (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). From a risk perspective, the adequacy of warnings regarding Reglan and TD is a central concern. The boxed warning is prominently placed in the prescribing information, but questions may arise about whether patients and prescribers were adequately informed of the risks, especially given that TD can occur even with short-term use in some individuals. The warning advises immediate discontinuation of Reglan if signs or symptoms of TD develop (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). However, because TD can be irreversible, early detection is critical. The label also warns against concomitant use of other drugs known to cause TD, extrapyramidal symptoms, or neuroleptic malignant syndrome, and advises avoiding use in patients with Parkinson's disease (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).
For affected patients in Ohio, attorney-related considerations include the statute of limitations for filing a claim. In Ohio, the statute of limitations for personal injury claims, including those related to medication-induced injuries like TD, is generally two years from the date the injury was discovered or should have been discovered. This timeline can be complex because TD may develop months or years after exposure to Reglan, and symptoms may be subtle initially. The timeline between exposure and documented harm is variable; some patients develop TD after only a few weeks of treatment, while others may experience onset after longer-term use. The boxed warning notes that risk increases with duration and cumulative dosage, but there is no guaranteed safe duration (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Patients who have been prescribed Reglan for longer than the recommended 12-week period may be at heightened risk. Given the potentially irreversible nature of TD and the availability of legal recourse, individuals who have developed TD after using Reglan should consult with an attorney experienced in pharmaceutical litigation. The attorney can evaluate whether the prescribing physician or manufacturer provided adequate warnings, and whether the statute of limitations has been met. The key evidence for such claims includes the FDA boxed warning, which clearly states the risk of TD and the recommended treatment duration limits (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Additionally, the prescribing information indicates that Reglan tablets are not recommended for pediatric patients due to the risk of TD and other extrapyramidal symptoms (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). In summary, Reglan is associated with a well-documented risk of tardive dyskinesia, which can be irreversible. The FDA-approved labeling includes a boxed warning and specific duration limits to mitigate this risk. Patients in Ohio who have developed TD after using Reglan should be aware of the statute of limitations and seek legal advice promptly. The evidence supports that the risk is dose- and duration-dependent, and that early discontinuation upon symptom onset is critical.
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
In Ohio, the statute of limitations for personal injury claims, including those related to Reglan-induced tardive dyskinesia, is generally two years from the date the injury was discovered or should have been discovered. Because TD can develop months or years after exposure, it is important to consult an attorney promptly to ensure your claim is filed within the applicable time frame.
Key evidence includes medical records documenting Reglan use and a diagnosis of tardive dyskinesia, as well as the FDA boxed warning which states the risk of TD and recommends limiting treatment duration to 12 weeks (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). An attorney can help gather and evaluate this evidence.
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.
Request archival records or inquire about member-exclusive transition and benefit programs.
Individuals with documented archive exposure and a related diagnosis may request an independent, no-cost eligibility review.